TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives $6.00 Average PT from Analysts

TScan Therapeutics, Inc. (NASDAQ:TCRX) has been assigned an average recommendation of “Hold” from the six research firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $6.00.

TCRX has been the subject of several research reports. Wall Street Zen downgraded shares of TScan Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Wedbush upped their price target on shares of TScan Therapeutics from $4.00 to $5.00 and gave the company an “outperform” rating in a research report on Thursday, March 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Tuesday, April 21st.

Hedge Funds Weigh In On TScan Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in TCRX. Goldman Sachs Group Inc. increased its position in TScan Therapeutics by 6.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock valued at $235,000 after acquiring an additional 9,676 shares during the period. JPMorgan Chase & Co. increased its position in TScan Therapeutics by 8.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 287,743 shares of the company’s stock valued at $417,000 after acquiring an additional 22,642 shares during the period. Marshall Wace LLP acquired a new position in TScan Therapeutics in the 2nd quarter valued at approximately $78,000. Qube Research & Technologies Ltd acquired a new position in TScan Therapeutics in the 2nd quarter valued at approximately $99,000. Finally, Jane Street Group LLC acquired a new position in TScan Therapeutics in the 2nd quarter valued at approximately $309,000. 82.83% of the stock is currently owned by institutional investors and hedge funds.

TScan Therapeutics Price Performance

Shares of NASDAQ:TCRX opened at $0.97 on Friday. The company has a market cap of $63.52 million, a price-to-earnings ratio of -1.01 and a beta of 1.03. The company has a debt-to-equity ratio of 0.34, a current ratio of 6.65 and a quick ratio of 6.65. The firm has a 50 day simple moving average of $1.10 and a 200 day simple moving average of $1.07. TScan Therapeutics has a one year low of $0.88 and a one year high of $2.57.

TScan Therapeutics (NASDAQ:TCRX) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, meeting the consensus estimate of ($0.22). The business had revenue of $0.98 million during the quarter, compared to the consensus estimate of $2.50 million. TScan Therapeutics had a negative net margin of 1,360.61% and a negative return on equity of 91.94%. Research analysts predict that TScan Therapeutics will post -1.11 earnings per share for the current fiscal year.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.